Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialRobin Kate Kelley, Ming‐Huang Chen, Abby B. Siegel et al.|The Lancet|2023Cited by 1k
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significanceThomas Litman, Susan E. Bates|Cellular and Molecular Life Sciences|2001Cited by 685
Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and DasatinibMarius Dohse, Susan E. Bates|Drug Metabolism and Disposition|2010Cited by 216
Histone deacetylase inhibitor‐mediated cell death is distinct from its global effect on chromatinVictoria Luchenko, Susan E. Bates|Molecular Oncology|2014Cited by 49
R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor RomidepsinMaryam Safari, Susan E. Bates|Molecular Cancer Research|2021Cited by 30